Tomasz M. Beer
YOU?
Author Swipe
View article: The impact of multicancer early detection tests on cancer stage shift: A 10‐year microsimulation model
The impact of multicancer early detection tests on cancer stage shift: A 10‐year microsimulation model Open
Introduction Early detection of cancer improves survival following diagnosis. However, routine screening is limited to a few cancer types. Multicancer early detection (MCED) tests could revolutionize cancer screening by simultaneously dete…
View article: TMPRSS2 Expression in Lung Tissue of Prostatic Adenocarcinoma Patients: Androgen Deprivation Therapy and Relevance to SARS-CoV-2 Infection
TMPRSS2 Expression in Lung Tissue of Prostatic Adenocarcinoma Patients: Androgen Deprivation Therapy and Relevance to SARS-CoV-2 Infection Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry is facilitated by transmembrane protease serine 2 (TMPRSS2), which is regulated by the androgen receptor (AR). Androgen deprivation therapy (ADT), widely used in p…
View article: Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry Open
PURPOSE Prostate cancer (PCA) germline testing (GT) informs precision therapy, cancer screening, and hereditary cancer risk for patients and families. To support patient-centered PCA GT, studying patient-reported outcomes (PROs) is essenti…
View article: Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohort
Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohort Open
Background Multi-target blood tests have the potential to detect a broad range of cancer types and stages. We previously trained and independently assessed the performance of four biomarker classes for cancer detection in a retrospectively…
View article: Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer Open
The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), …
View article: TMPRSS2 Expression in Lung Tissue of Prostatic Adenocarcinoma Patients: A Pathologic Perspective on Androgen Deprivation Therapy
TMPRSS2 Expression in Lung Tissue of Prostatic Adenocarcinoma Patients: A Pathologic Perspective on Androgen Deprivation Therapy Open
Context Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry is facilitated by transmembrane protease serine 2 (TMPRSS2), which is regulated by the androgen receptor (AR). Androgen deprivation therapy (ADT), widely u…
View article: Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection Open
In recent years, there has been a surge in the development of new, blood-based, single- and multi-cancer detection tests (SCD and MCD), which can detect cancer signals prior to the onset of symptoms or clinical diagnosis of cancer. Recogni…
View article: Multi-cancer early detection tests: Attributes for clinical implementation
Multi-cancer early detection tests: Attributes for clinical implementation Open
Guideline-recommended screening programs exist for only a few single-cancer types, and these cancers represent less than one-half of all new cancer cases diagnosed each year in the U.S. In addition, these “single-cancer” standard of care (…
View article: Tumor localization strategies of multicancer early detection tests: a quantitative assessment
Tumor localization strategies of multicancer early detection tests: a quantitative assessment Open
Background Multicancer early detection tests may expand cancer screening. Characterizing diagnostic resolution approaches following positive multicancer early detection tests is critical. Two trials employed distinct resolution approaches:…
View article: Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now Open
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for man…
View article: Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study Open
Background Androgen receptor inhibitors (ARIs) are approved for the treatment of advanced prostate cancer; however, some patients may experience symptoms and side effects that hinder their physical functioning. The Timed Up and Go (TUG) an…
View article: Pre-malignant conditions diagnosed following a positive cancer signal from a multi-cancer early detection test
Pre-malignant conditions diagnosed following a positive cancer signal from a multi-cancer early detection test Open
Blood-based tests for multi-cancer early detection (MCED) are being developed to facilitate the detection of various cancer types. The Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing study (DETECT-A) …
View article: Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance
Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance Open
Prostate cancer continues to be one of the most lethal cancers in men. While androgen deprivation therapy is initially effective in treating prostate cancer, most cases of advanced prostate cancer eventually progress to castration‐resistan…
View article: Supplementary Figure 4. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 4. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Gene Ontology (GO) with Biological processes (BP) on the genes uniquely up- or down-regulated within each subtype
View article: Supplementary Figure 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Volcano plots representing the differentially expressed (DE) genes in the mCRPC subtypes compared to AR+/NE- tumors
View article: Supplementary Data 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Data 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
List of Differentially expressed genes in the subtypes of mCRPC in comparison with AR+/NE- tumors
View article: Supplementary Figure 2. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 2. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation
View article: Supplementary Data 2. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Data 2. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
List of enriched motifs identified in the hyper- and hypo-methylated regions of mCRPC subtypes
View article: Supplementary Figure 6. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 6. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Gene expression level of CHD7 among the mCRPC tumors of Beltran et al. cohort
View article: Supplementary Figure 8. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 8. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Gene expression level of Krüppel-like factor (KLF) family among the five mCRPC subtypes
View article: Supplementary Figure 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Volcano plots representing the differentially expressed (DE) genes in the mCRPC subtypes compared to AR+/NE- tumors
View article: Supplementary Table 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Table 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
ETS family fusions detected in the WCDT samples
View article: Data from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Data from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era Open
Cancer is a significant burden worldwide that adversely impacts life expectancy, quality of life, health care costs and workforce productivity. While currently recommended screening tests for individual cancers reduce mortality, they detec…
View article: Supplementary Table 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Table 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Clinical characteristics of samples in WCDT cohort
View article: Supplementary Figure 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 1. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Hierarchical clustering and principal component analyses (PCA) on the mCRPC tumors of WCDT cohort.
View article: Supplementary Table S1 from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Supplementary Table S1 from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era Open
Cancer types detected incidentally by NIPT
View article: Supplementary Figure 6. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 6. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Gene expression level of CHD7 among the mCRPC tumors of Beltran et al. cohort
View article: Supplementary Table S1 from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Supplementary Table S1 from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era Open
Cancer types detected incidentally by NIPT
View article: Supplementary Table 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Table 3. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
ETS family fusions detected in the WCDT samples
View article: Supplementary Figure 5. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer
Supplementary Figure 5. from The genomic and epigenomic landscape of double-negative metastatic prostate cancer Open
Gene expression level of SOX2 among the tumor subtypes of WCDT samples